Cape Heart Institute, Department of Medicine & Cardiology, Faculty of Health Science, University of Cape Town, Cape Town, 7700, South Africa.
Department of Adult Cardiology, Uganda Heart Institute, Kampala, 7051, Uganda.
Future Oncol. 2022 Aug;18(24):2675-2685. doi: 10.2217/fon-2022-0116. Epub 2022 Jul 7.
To investigate the incidence of anthracycline therapy-related cardiac dysfunction (ATRCD) and its predictors among Ugandan cancer patients. The study recruited 207 cancer patients who were followed for 6 months after ending anthracycline therapy. Global longitudinal strain and troponin-I were the diagnostic tools. The cumulative incidences of subclinical and clinical ATRCD were 35.0 and 8.8% respectively. The predictors of clinical ATRCD were HIV infection (hazard ratio [HR]: 3.04; 95% CI: 1.26-7.32; p = 0.013), lower baseline global longitudinal strain (HR: 0.61; 95% CI: 0.53-0.71; p < 0.001) and development of subclinical ATRCD at the end of anthracycline therapy (HR: 6.61; 95% CI: 2.60-16.82; p < 0.001). Cardiac surveillance at baseline and at ending of anthracycline therapy is essential to identify high-risk patients.
研究目的在于探究乌干达癌症患者接受蒽环类药物治疗相关心脏功能障碍（ATRCD）的发生率及其预测因素。该研究共纳入 207 例癌症患者，在结束蒽环类药物治疗后随访 6 个月。采用整体纵向应变和肌钙蛋白 I 作为诊断工具。亚临床和临床 ATRCD 的累积发生率分别为 35.0%和 8.8%。临床 ATRCD 的预测因素为 HIV 感染（风险比 [HR]：3.04；95%可信区间 [CI]：1.26-7.32；p=0.013）、基线整体纵向应变较低（HR：0.61；95% CI：0.53-0.71；p<0.001）和蒽环类药物治疗结束时出现亚临床 ATRCD（HR：6.61；95% CI：2.60-16.82；p<0.001）。在基线和蒽环类药物治疗结束时进行心脏监测对于识别高危患者至关重要。
